PE20230370A1 - Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias - Google Patents

Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias

Info

Publication number
PE20230370A1
PE20230370A1 PE2022001452A PE2022001452A PE20230370A1 PE 20230370 A1 PE20230370 A1 PE 20230370A1 PE 2022001452 A PE2022001452 A PE 2022001452A PE 2022001452 A PE2022001452 A PE 2022001452A PE 20230370 A1 PE20230370 A1 PE 20230370A1
Authority
PE
Peru
Prior art keywords
amino acid
interleukin
inflammatory diseases
peptide inhibitors
treat inflammatory
Prior art date
Application number
PE2022001452A
Other languages
English (en)
Spanish (es)
Inventor
Chengzao Sun
Brian Troy Frederick
Sandeep Somani
Gregory Thomas Bourne
Raymond Patch
Ashok Bhandari
Raffaele Ingenito
Roberto Costante
Danila Branca
Elisabetta Bianchi
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of PE20230370A1 publication Critical patent/PE20230370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2022001452A 2020-01-15 2021-01-14 Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias PE20230370A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961624P 2020-01-15 2020-01-15
PCT/US2021/013463 WO2021146441A1 (en) 2020-01-15 2021-01-14 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
PE20230370A1 true PE20230370A1 (es) 2023-03-06

Family

ID=76864704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001452A PE20230370A1 (es) 2020-01-15 2021-01-14 Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias

Country Status (32)

Country Link
US (2) US11845808B2 (enExample)
EP (2) EP4613761A2 (enExample)
JP (2) JP7441955B2 (enExample)
KR (1) KR20220141807A (enExample)
CN (5) CN118027153A (enExample)
AR (1) AR121070A1 (enExample)
AU (1) AU2021207653A1 (enExample)
CA (1) CA3167751A1 (enExample)
CL (2) CL2022001893A1 (enExample)
CO (1) CO2022009931A2 (enExample)
CR (1) CR20220332A (enExample)
DK (1) DK4090670T3 (enExample)
DO (1) DOP2022000147A (enExample)
EC (1) ECSP22063238A (enExample)
ES (1) ES3036287T3 (enExample)
FI (1) FI4090670T3 (enExample)
HR (1) HRP20250769T1 (enExample)
HU (1) HUE072238T2 (enExample)
IL (1) IL294680A (enExample)
JO (1) JOP20220169A1 (enExample)
LT (1) LT4090670T (enExample)
MA (1) MA58373B1 (enExample)
MX (1) MX2022008741A (enExample)
PE (1) PE20230370A1 (enExample)
PH (1) PH12022551750A1 (enExample)
PL (1) PL4090670T3 (enExample)
PT (1) PT4090670T (enExample)
RS (1) RS66991B1 (enExample)
SI (1) SI4090670T1 (enExample)
SM (1) SMT202500254T1 (enExample)
TW (2) TW202515892A (enExample)
WO (1) WO2021146441A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707622XA (en) 2013-03-15 2017-11-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
MX2022000397A (es) * 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4613761A2 (en) 2020-01-15 2025-09-10 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
KR20240034222A (ko) * 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 펩티드 억제제
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
US20240327369A1 (en) * 2021-07-23 2024-10-03 Blackstone Therapeutics, Llc A method for preparing hexahydrocannabinol
CN118354781A (zh) 2021-12-01 2024-07-16 西兰制药公司 白介素-23受体的肽抑制剂
KR20240137102A (ko) 2022-02-01 2024-09-19 얀센 파마슈티카 엔브이 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물
US20250206692A1 (en) * 2022-03-14 2025-06-26 Colorado Chromatography, Llc Hydrogenation of cannabigerol and cannabichromene
JP2025521647A (ja) 2022-06-30 2025-07-10 サノフイ 選択的ｉｌ－２３受容体アンタゴニストとしての新規ペプチド
EP4622991A2 (en) * 2022-11-21 2025-10-01 Janssen Pharmaceutica NV Synthesis of a cyclic peptide
TW202440611A (zh) * 2022-11-30 2024-10-16 大陸商上海翰森生物醫藥科技有限公司 多肽抑制劑、其製備方法和應用
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
EP4652182A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
AU2024214418A1 (en) 2023-01-31 2025-09-18 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor
TW202448428A (zh) * 2023-03-03 2024-12-16 比利時商健生藥品公司 使用介白素－２３受體拮抗劑之方法
WO2024227437A1 (zh) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051912A1 (en) * 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025163534A1 (en) 2024-01-31 2025-08-07 Janssen Pharmaceutica Nv Crystal form of a peptide inhibitor of interleukin-23 receptor
WO2025243217A1 (en) * 2024-05-22 2025-11-27 Janssen Pharmaceutica Nv Crystal forms of peptide molecules
CN120905324A (zh) * 2025-10-10 2025-11-07 北京元延医药科技股份有限公司 白细胞介素-23受体肽抑制剂及其手性中间体的制法

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
DK0578728T3 (da) 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
DK0644772T3 (da) 1992-11-12 2003-06-30 Sod Conseils Rech Applic Opioid-peptider
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
AU8399998A (en) 1997-07-11 1999-02-08 Innerdyne, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
US6271252B1 (en) 1997-11-24 2001-08-07 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
WO2000006243A2 (en) 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
CN1350534A (zh) 1999-04-12 2002-05-22 阿文蒂斯药物有限公司 作为整联蛋白拮抗剂的取代双环杂芳基化合物
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
EP1523557A2 (en) 2002-07-24 2005-04-20 Intercell AG Antigens encoded by alternative reading frame from pathogenic viruses
AU2003301059A1 (en) 2002-12-18 2004-07-22 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
JP2006523440A (ja) 2003-04-15 2006-10-19 ゼノン ファーマスーティカルス，インコーポレイテッド 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法
CA2830063C (en) 2003-11-05 2017-10-31 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1695255B1 (en) 2003-12-19 2016-09-07 Applied Biosystems, LLC Methods and systems for protein and peptide evidence assembly
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
AU2005256155A1 (en) 2004-06-24 2006-01-05 The Walter And Eliza Hall Institute Of Medical Research Conjugates and therapeutic uses thereof
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20080300180A1 (en) 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP2016177A2 (en) 2006-04-12 2009-01-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
US8304382B2 (en) 2006-07-21 2012-11-06 Cristalia Productos Quimicos Farmaceuticos Ltda. Anti-inflammatory and anti-allergic cyclic peptides
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2392597B1 (en) 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2008144041A1 (en) 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
US20100190710A1 (en) 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
CA2741566A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN102245626A (zh) 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
CN102459311B (zh) 2009-04-08 2015-08-19 武田药品工业株式会社 神经调节肽u衍生物
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104725472A (zh) 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
US20130236977A1 (en) 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20150118315A1 (en) 2011-06-14 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2855122A1 (en) 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CN105378159A (zh) 2013-02-15 2016-03-02 Srx心脏有限责任公司 调节血清低密度脂蛋白（LDL）水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型（PCSK9）变构结合配体
SG10201707622XA (en) 2013-03-15 2017-11-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
DK3013351T3 (da) 2013-06-24 2020-01-27 Canbas Co Ltd Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160235807A1 (en) 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CN107075574A (zh) 2014-06-27 2017-08-18 领导医疗有限公司 铁调素和微型铁调素类似物及其用途
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
CA2970962A1 (en) 2014-12-29 2016-07-07 The Regents Of The University Of California S-alkylated hepcidin peptides and methods of making and using thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016293619B2 (en) * 2015-07-15 2021-02-25 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (zh) 2016-03-23 2019-01-11 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
US20190270786A1 (en) 2016-07-27 2019-09-05 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20190264197A1 (en) 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
AU2017371472B2 (en) 2016-12-06 2024-08-08 Universiteit Van Amsterdam Multicyclic peptides and methods for their preparation
JP2020505352A (ja) 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
JP7670605B2 (ja) 2018-07-12 2025-04-30 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
CN113631569A (zh) 2019-03-28 2021-11-09 领导医疗有限公司 用于合成β-高氨基酸的方法
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2022546878A (ja) 2019-09-03 2022-11-09 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物
AU2021205415A1 (en) 2020-01-10 2022-07-21 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4613761A2 (en) 2020-01-15 2025-09-10 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20230053615A (ko) 2020-07-28 2023-04-21 프로타고니스트 테라퓨틱스, 인코포레이티드 접합된 헵시딘 모방체
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
JP2024513392A (ja) 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
TW202317604A (zh) 2021-06-14 2023-05-01 美商領導醫療公司 用於治療遺傳性血鐵沉積症之鐵調素模擬物

Also Published As

Publication number Publication date
SMT202500254T1 (it) 2025-09-12
RS66991B1 (sr) 2025-08-29
CN118027153A (zh) 2024-05-14
BR112022013957A2 (pt) 2022-10-11
JP7441955B2 (ja) 2024-03-01
IL294680A (en) 2022-09-01
JOP20220169A1 (ar) 2023-01-30
PL4090670T3 (pl) 2025-07-28
EP4090670B1 (en) 2025-06-04
ECSP22063238A (es) 2022-09-30
EP4090670A1 (en) 2022-11-23
DK4090670T3 (da) 2025-06-30
PT4090670T (pt) 2025-07-29
CN118005736A (zh) 2024-05-10
CL2024004039A1 (es) 2025-05-09
CN115298196A (zh) 2022-11-04
HUE072238T2 (hu) 2025-11-28
EP4090670A4 (en) 2024-11-20
MX2022008741A (es) 2022-10-03
AU2021207653A1 (en) 2022-08-04
TWI882061B (zh) 2025-05-01
ES3036287T3 (en) 2025-09-17
TW202515892A (zh) 2025-04-16
CL2022001893A1 (es) 2023-03-03
CO2022009931A2 (es) 2022-10-21
KR20220141807A (ko) 2022-10-20
SI4090670T1 (sl) 2025-08-29
US20210261622A1 (en) 2021-08-26
JP2023511552A (ja) 2023-03-20
CN118063554A (zh) 2024-05-24
US20240150405A1 (en) 2024-05-09
JP2023139158A (ja) 2023-10-03
CR20220332A (es) 2022-11-28
DOP2022000147A (es) 2023-01-15
EP4613761A2 (en) 2025-09-10
WO2021146441A1 (en) 2021-07-22
CA3167751A1 (en) 2021-07-22
AR121070A1 (es) 2022-04-13
HRP20250769T1 (hr) 2025-08-29
EP4613761A9 (en) 2025-10-22
LT4090670T (lt) 2025-08-11
MA58373B1 (fr) 2025-07-31
FI4090670T3 (fi) 2025-07-23
CN118005737A (zh) 2024-05-10
TW202140517A (zh) 2021-11-01
US11845808B2 (en) 2023-12-19
PH12022551750A1 (en) 2023-11-13

Similar Documents

Publication Publication Date Title
PE20230370A1 (es) Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
PE20240631A1 (es) Composiciones de inhibidores peptidicos del receptor de interleucina-23
MX2024000762A (es) Inhibidores peptidicos del receptor de interleucina-23.
AR126457A1 (es) Inhibidores peptídicos bicíclicos del receptor de interleuquina-23
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
CL2024002263A1 (es) Inhibidores peptídicos del receptor de interleucina-23 y composiciones farmacéuticas de los mismos.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
CO2023013356A2 (es) Compuestos para la inhibición de nlrp3 y usos de estos
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
CL2017003201A1 (es) Variantes de il-37
PE20220431A1 (es) Compuestos inhibidores de la masp y usos de estos
CL2019003562A1 (es) Derivados esteroideos con actividad terapéutica.
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
IL308290A (en) Ionic liquid formulations for treating inflammatory and autoimmune diseases
MX2025005020A (es) Inhibidores de cromanona alostericos de fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
EA202192057A1 (ru) Карбаматные производные и их применение
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.
CO2025010249A2 (es) Inhibidores peptídicos del receptor de interleucina-23
DOP2025000151A (es) Inhibidores peptídicos del receptor de interleucina-23
MX2025010360A (es) Peptidos antagonistas del receptor de interleucina-23 para usar en el tratamiento de la psoriasis
MX2025013162A (es) Preparacion de peptido inhibidor del receptor de interleucina-23 y uso del mismo
Abaeva et al. FERMENTATIVNYE ASPEKTY PATOGENEZA PROLAPSA GENITALIY
CO2018005104A1 (es) Dispositivo para procedimientos de circuncisión
UY27371A1 (es) Derivados de ácido cicloalquilpirrol-3-carboxílico y derivados de ácido heterocicloalquilpirrol-3-carboxílico